Test, developed by Japanese multinational Fujirebio Diagnostics, measures the proportion of two proteins in the blood
Approved them, this Friday (16), the use of the first blood test to detect the a measure that can help patients start treatment earlier with recently approved drugs that slow the progression of this devastating neurological disease. The test, developed by the Japanese multinational Fujirebio Diagnostics, measures the proportion of two proteins in the blood. This proportion correlates with amyloid plates in the brain, a distinctive feature of Alzheimer’s that could only be detected by special image tests or by the analysis of cephalorchid liquid. “Alzheimer affects many people, more than breast cancer and prostate cancer together,” said Marty Makary, commissioner of the Federal Regulatory Agency Food and Medicines Administration (FDA).
According to Makary, “knowing that 10% of people over 65 suffer from Alzheimer’s, and it is hoped that by 2050 this number will double, I hope that new medical products like this will help patients.” Currently, there are two treatments approved by FDA for Alzheimer’s: Lecanemab and Donanemab medicines, which act on the amyloid plate and have been a little delayed the cognitive decline, although they do not core the disease. Defenders of intravenous antibody therapies, including many neurologists, argue that these treatments can offer patients a few additional months of independence and possibly more effective if initiated at Alzheimer’s early stages.
*With information from AFP
Posted by Sarah Paula
